Global Cell Therapy Market Report 2020: Market is Expected to Decline from $7.31 Billion in 2019 to $7.2 Billion in 2020 at a CAGR of -1.54%
17 déc. 2020 06h13 HE
|
Research and Markets
Dublin, Dec. 17, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Cell Therapy...
Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio
03 déc. 2020 09h00 HE
|
Taconic Biosciences
RENSSELAER, New York, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the new ExpressMODEL®: Random...
HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
30 nov. 2020 14h47 HE
|
Excision BioTherapeutics
San Francisco, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV –...
Cell Therapy and Gene Therapy Markets, 2030
06 nov. 2020 06h28 HE
|
Research and Markets
Dublin, Nov. 06, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy and Gene Therapy Markets" report has been added to ResearchAndMarkets.com's offering. The report examines developments in cell and gene...
Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D
21 sept. 2020 05h18 HE
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line...
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
10 août 2020 06h35 HE
|
LogicBio Therapeutics
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating...
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
10 août 2020 06h30 HE
|
LogicBio Therapeutics
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with...
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
23 juin 2020 09h18 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , June 23, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
11 mai 2020 16h10 HE
|
LogicBio Therapeutics
LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare...
Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
11 mars 2020 15h27 HE
|
Excision BioTherapeutics
OAKLAND, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a private biotechnology company focused on applying CRISPR gene editing to curing viral infectious diseases, today...